Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 235 publications
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Journal: JAMA network open
Published: July 16, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2026
Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.
Journal: Frontiers in immunology
Published: April 06, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.
Journal: NPJ precision oncology
Published: December 10, 2025
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
Journal: The oncologist
Published: September 30, 2025
Biomarker study of pembrolizumab in patients with advanced rare cancers.
Journal: Cell reports. Medicine
Published: September 24, 2025
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
Journal: NPJ precision oncology
Published: September 09, 2025
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations.
Journal: ESMO open
Published: August 13, 2025
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.
Journal: Signal transduction and targeted therapy
Published: August 12, 2025
Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion.
Journal: The oncologist
Published: April 16, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion.
Journal: The oncologist
Published: April 16, 2025
Last Updated: 09/26/2026